1-Aethyl-pyrimidin-2-on | 3846-62-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-Aethyl-pyrimidin-2-on
• 英文别名: 1-Ethyl-1,2-dihydro-2-oxo-pyrimidin；2-Aethyl-2-oxo-1,2-dihydro-pyrimidin；2-Aethyl-1,2-dihydro-2-oxo-pyrimidin；1-ethyl-1H-pyrimidin-2-one；Pyrimidine, 1-ethyl-1,2-dihydro-2-oxo-；1-ethylpyrimidin-2-one
• CAS: 3846-62-6
• 化学式: C₆H₈N₂O
• 分子量: 124.142
• InChiKey: FZEWJPWEKUSGSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] HYDROXYMÉTHYLPYRROLIDINES EN TANT QU'AGONISTES DE RÉCEPTEUR BÊTA-3-ADRÉNERGIQUE
  申请人：MERCK & CO INC

  公开号：WO2009123870A1

  公开（公告）日：2009-10-08

  The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了式I的化合物，其药物组成物以及使用该化合物在治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。
• [EN] OXAZOLIDINONE COMPOUNDS AND THEIR USES IN PHARMACEUTICALS<br/>[FR] COMPOSÉS D'OXAZOLIDINONE ET LEURS UTILISATIONS EN PHARMACEUTIQUE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015110024A1

  公开（公告）日：2015-07-30

  The invention relates to the field of blood coagulation, more specifically it relates to novel oxazolidinone compounds or a pharmaceutically acceptable salt thereof, and their uses in the manufacture of medicaments for treating thromboembolic disorders or inhibiting factor Xa.

  该发明涉及血液凝固领域，更具体地涉及新型噁唑烷酮化合物或其药用盐以及它们在制造治疗血栓栓塞性疾病或抑制因子Xa的药物中的用途。
• 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100267668A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I). wherein: X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：X、R1、R2、R3和R4如规范中所定义。该发明还包括一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病是II型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用至少一种式(I)化合物的治疗有效量来抑制CCR2活性的方法。
• 1,2,3-TRIAZOLE PYRROLIDINE DERIVATIVES AS MODULATORS OF MGLUR5
  申请人：BRATT Emma

  公开号：US20090111822A1

  公开（公告）日：2009-04-30

  The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

  本发明涉及新化合物，其制备方法，它们在治疗中的使用以及包含这些新化合物的制药组合物。
• [EN] CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE<br/>[FR] COMPOSÉS CONTENANT DE L'ACIDE CARBOXYLIQUE UTILISÉS EN TANT QUE MODULATEURS DE LA BIS-PHOSPHOGLYCÉRATE MUTASE POUR LE TRAITEMENT DE LA DRÉPANOCYTOSE
  申请人：GENZYME CORP

  公开号：WO2022056447A1

  公开（公告）日：2022-03-17

  Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.

  本文提供了用于调节双磷酸甘油酸变异酶（BPGM）以治疗镰状细胞贫血的化合物和其组合物。